Latest Safety News

Radiopharm Theranostics has secured Data Safety and Monitoring Committee approval to escalate dosing in its Phase 1 trial of 177Lu-RAD204, expanding patient cohorts across multiple cancer types.

Dyno Nobel Limited reported a $25 million EBIT uplift in its 2025 half-year results, driven by its ongoing transformation program and strategic moves to separate its Fertilisers business. Despite weather-related challenges, the company is progressing key asset sales and preparing for a share buyback resumption.

Dyno Nobel Limited reports a statutory net profit of $7 million for 1H25, reversing a prior loss, as it advances key sales agreements to separate its Fertilisers business and accelerates its transformation program.

Austco Healthcare has renewed its preferred supplier agreement with a major US healthcare provider, continuing supply of its Tacera nurse call systems to 180 hospitals across 30 states. This extension builds on a lucrative five-year partnership worth over A$49 million.

Torque Metals has won a $144,500 co-funded drilling grant from the Western Australian government to explore down-plunge extensions of high-grade gold at its Paris Gold Project, potentially expanding its resource base.

Nyrada’s experimental drug NYR-BI03 shows promising cardioprotective and anti-arrhythmic effects in animal models, reinforcing its potential as a treatment for acute myocardial infarction.

Transurban Group is streamlining operations with a workforce reduction of around 300 roles, targeting over $50 million in annual cost savings while maintaining its FY25 distribution guidance.

Transurban Group is streamlining operations with a workforce reduction of approximately 300 employees, aiming to save over $50 million annually while maintaining its FY25 distribution guidance.

Orica Limited reported its strongest half-year EBIT in over a decade, driven by robust demand for premium blasting products and technology adoption, alongside significant safety and sustainability achievements.

Orica Limited reported a robust first half FY2025 with a 40% rise in NPAT pre-significant items and strong cash flow, underpinned by demand for premium blasting and digital solutions. The company also announced a $400 million share buy-back and a 32% higher interim dividend.

Spectur Limited appoints Anthony Schmidt as CEO, accelerating its transition to a scalable SaaS model and targeting operational cashflow neutrality by mid-2025 amid a $3 billion addressable market.

Alterity Therapeutics is set to present compelling Phase 2 clinical trial results for ATH434 at the 2025 International Multiple System Atrophy Congress, highlighting slowed disease progression and biomarker engagement in MSA patients.